Related Experiment Video
Updated: Jun 29, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Iowa Newborn Screening Program Experience with Hemoglobinopathy Screening over the Last Two Decades and Its
Ryan Jilek1, Jennifer Marcy2,3, Carol Johnson2,3
1Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Abstract:
Hemoglobinopathies are the commonest monogenic disorder worldwide, with approximately seven percent of the world population being carriers of hemoglobinopathies. The healthcare utilization impact of thalassemia has resulted in global public health initiatives to screen for hemoglobinopathies, especially sickle cell disease (SCD). The Iowa Newborn Screening Program (INSP) has been in place for more than 50 years with a primary focus on detecting SCD. Recent changes in migration patterns have led to a global distribution of hemoglobinopathies in the western world, which has translated to an increase in the diagnosis of SCD and the incidental detection of non-sickling hemoglobinopathies within the INSP. This study documents the birth prevalence of hemoglobinopathies diagnosed in newborns through the INSP and highlights the need for newborn screening programs to evolve to meet the healthcare needs of underserved, minority populations.
Related Concept Videos
Rh Blood Group
iPS Cell Differentiation

